Biotech Values

[genisi]

ORR in ITT population is 22.9% in the FDA analysis, and in the 'truly' unmet need (patients unresponsive or intolerant to approved agents) is above 20% in all subgroups, so I think the efficacy demand is met but seems it may not justify the risk for cardiotox in the FDA's view and chances are quite high they will want more data.